Medscape is available in 5 Language Editions – Choose your Edition here.


Prosthetic Heart Valves Follow-up

  • Author: Eric M Kardon, MD, FACEP; Chief Editor: Richard A Lange, MD, MBA  more...
Updated: Feb 18, 2015

Further Outpatient Care

Following valve replacement, every patient should undergo a history, physical examination, and appropriate testing at the first postoperative visit (2-4 wk after hospital discharge). An echocardiographic examination should be performed at this time. Thereafter, follow-up visits are recommended annually, or earlier (with echocardiography) if new symptoms develop that are attributable to a potential valvular dysfunction. In patients with a bioprosthetic valve, annual echocardiograms may be considered after the first 5 years in the absence of any changes in clinical status.[9]

Patients with postoperative LV dysfunction should be treated with standard therapy for systolic heart failure, even if improved or asymptomatic.[9]

Although the risk of thromboembolic events is lower in patients with a bioprosthetic valve than in those with a mechanical prosthesis, low-dose aspirin (75-100 mg/d) is indicated in patients without thromboembolic risk factors (eg, atrial fibrillation, previous thromboembolism, hypercoagulable condition). Although the risk of early embolic events is relatively low in patients treated with aspirin only, the addition of warfarin at hospital discharge reduces the incidence of early embolic events, but that benefit is balanced by an increased risk of repeat hospitalization for bleeding.[23] For patients with risk factors, warfarin is indicated to achieve an international normalized ratio (INR) of 2.0 to 3.0, whether after AVR or MR. Alternatively, aspirin in a dose of 75-325 mg per day is indicated in patients who are unable to take warfarin.

All patients with prosthetic valves should receive antibiotic prophylaxis against infective endocarditis prior to dental procedures.



Initiate arrangements for transfer to a center with cardiac surgical capabilities in patients presenting with moderate-to-severe hemodynamic compromise if these services are not readily available.

The mortality rate in patients with acute prosthetic valvular failure is related directly to the delay of surgical correction.



Provide antibiotic prophylaxis to patients undergoing procedures that may result in bacteremia. The following list, although not exhaustive, includes most inpatient and outpatient procedures performed in the ED that may result in bacteremia and, therefore, may lead to prosthetic valve endocarditis (PVE)[24] :

  • Dental and oral procedures
  • Respiratory procedures, particularly those which involve disruption of the respiratory mucosal surface, or when a known infection is present. If a known infection caused by Staphylococcus aureus is present, prophylaxis with an antistaphylococcal penicillin, cephalosporin, or vancomycin should be given. In cases of known or suspected methicillin-resistant Staphylococcus aureus, prophylaxis with vancomycin should be given.
  • Sclerotherapy of bleeding esophageal varices
  • Routine prophylaxis for gastrointestinal or genitourinary procedures is no longer recommended, unless in the presence of a known infection [25] : Urethral catheterization in the presence of a suspected urinary tract infectio; vaginal delivery in the presence of infection
  • Incision and drainage of infected tissues
  • For dental, oral, or upper respiratory tract procedures, use amoxicillin 2 g PO 30-60 minutes before the procedure. If the patient is unable to take PO medication, use ampicillin 2 g IM/IV OR cefazolin 1 g IM/IV, OR ceftriaxone 1 g IM/IV 30-60 minutes before the procedure. For penicillin-allergic patients, use clindamycin 600 mg PO/IM/IV OR azithromycin 500 mg PO OR clarithromycin 500 mg PO OR cephalexin 2 g PO 30-60 minutes before the procedure. (These are all single-dose regimens.) Do not use cephalexin in patients with a documented significant allergy to penicillin unless there is documentation that the patient can tolerate cephalosporins.
  • Further guidelines on the prevention, diagnosis, and treatment of infective endocarditis are available from the American Heart Association and the European Society of Cardiology. [24, 26]


Complications of prosthetic valves include primary valve failure, prosthetic valve endocarditis (PVE), prosthetic valve thrombosis, thromboembolism, and mechanical hemolytic anemia. In addition, anticoagulant-related hemorrhage may occur.

Primary valve failure may occur abruptly from the tearing or breakage of components or from a thrombus suddenly impinging on leaflet mobility. More commonly, valve failure presents gradually from calcifications or thrombus formation. Bioprostheses are less thrombogenic than mechanical valves, but this advantage is balanced by their diminished durability when compared with mechanical valves. Primary valve failure occurs in 3-4% of patients with bioprostheses within 5 years of implantation and in up to 35% of patients within 15 years. In contrast, it is anticipated that most mechanical valves will remain functional for 20-30 years.

When the mitral valve fails acutely, rapid left atrial volume overload causes increased left atrial pressure. Pulmonary venous congestion and, ultimately, pulmonary edema ensue. Cardiac output is decreased, because a portion of the LV output is regurgitated into the left atrium. The compensatory mechanism of increased sympathetic tone increases the heart rate and the systemic vascular resistance (SVR). This may worsen the situation by decreasing diastolic filling time and impeding LV outflow, thereby increasing the regurgitation.

Acute failure of a prosthetic aortic valve causes a rapidly progressive LV volume overload. Increased LV diastolic pressure results in pulmonary congestion and edema. The cardiac output is reduced substantially. The compensatory mechanism of an increased heart rate and a positive inotropic state, mediated by increased sympathetic tone, partly helps to maintain output. However, this is hampered by an increase in SVR, which impedes forward flow. Increased systolic wall tension causes a rise in myocardial oxygen consumption. Myocardial ischemia may follow acute aortic regurgitation, even in the absence of coronary artery disease.

Stenosis or incompetence of prosthetic valves may develop as a result of a tear or perforation of the valve cusp, valvular thrombosis, pannus formation, valve calcification, or stiffening of the leaflets.

PVE occurs in 2-4% of patients. The incidence is 3% in the first postoperative year, then 0.5% for subsequent years. The incidence is higher in mitral valves. Mechanical and biological valves are equally susceptible. PVE occurring within 60 days of implantation (early PVE) usually is due to perioperative contamination or hematogenous spread. PVE occurring after 60 days (late PVE) usually is caused by hematogenous spread. Glomerulonephritis, CHF, mycotic aneurysms, and metastatic abscesses may complicate PVE.

Bioprosthetic valve endocarditis usually causes leaflet tears or perforations. Valve stenosis is more common with bioprosthetic valves than with mechanical valves. Ring abscess, purulent pericarditis, and myocardial abscesses are much less frequent in bioprosthetic valve endocarditis.

Contributor Information and Disclosures

Eric M Kardon, MD, FACEP Attending Emergency Physician, Georgia Emergency Medicine Specialists; Physician, Division of Emergency Medicine, Athens Regional Medical Center

Eric M Kardon, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Medical Association of Georgia

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

A Antoine Kazzi, MD Deputy Chief of Staff, American University of Beirut Medical Center; Associate Professor, Department of Emergency Medicine, American University of Beirut, Lebanon

A Antoine Kazzi, MD is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Richard A Lange, MD, MBA President, Texas Tech University Health Sciences Center, Dean, Paul L Foster School of Medicine

Richard A Lange, MD, MBA is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Heart Association, Association of Subspecialty Professors

Disclosure: Nothing to disclose.


Mary C Mancini, MD, PhD

Professor and Chief of Cardiothoracic Surgery, Department of Surgery, Louisiana State University School of Medicine in Shreveport

Mary C Mancini, MD, PhD is a member of the following medical societies: American Association for Thoracic Surgery, American College of Surgeons, American Surgical Association, Phi Beta Kappa, and Society of Thoracic Surgeons

Disclosure: Nothing to disclose.

Judy Lin, MD

Disclosure: Nothing to disclose.

  1. Chiang YP, Chikwe J, Moskowitz AJ, Itagaki S, Adams DH, Egorova NN. Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years. JAMA. 2014 Oct 1. 312(13):1323-9. [Medline].

  2. O'Riordan M. Survival and stroke rates equivalent at 15 years with mechanical and bioprosthetic aortic valves. Heartwire. September 30, 2014. [Full Text].

  3. O’Riordan M. SCCT policy statement recommends CT prior to TAVI/TAVR procedures. Medscape Medical News. Jan 11, 2013. [Full Text].

  4. Achenbach S, Delgado V, Hausleiter J, Schoenhagen P, Min JK, Leipsic JA. SCCT expert consensus document on computed tomography imaging before transcatheter aortic valve implantation (TAVI)/transcatheter aortic valve replacement (TAVR). J Cardiovasc Comput Tomogr. 2012 Nov. 6(6):366-80. [Medline].

  5. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH,. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb. 141(2 Suppl):e576S-600S. [Medline].

  6. Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Härtter S, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012 Jun. 163(6):931-937.e1. [Medline].

  7. Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol. 2010 Jun 1. 55(22):2413-26. [Medline].

  8. Pibarot P, Dumesnil JG. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation. 2009 Feb 24. 119(7):1034-48. [Medline].

  9. [Guideline] Bonow RO, Carabello BA, Chatterjee K, et al for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008 Sep 23. 52(13):e1-142. [Medline]. [Full Text].

  10. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 2000 Oct. 36(4):1152-8. [Medline].

  11. Oxenham H, Bloomfield P, Wheatley DJ, et al. Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. Heart. 2003 Jul. 89(7):715-21. [Medline]. [Full Text].

  12. Bates MG, Matthews IG, Fazal IA, Turley AJ. Postoperative permanent pacemaker implantation in patients undergoing trans-catheter aortic valve implantation: what is the incidence and are there any predicting factors?. Interact Cardiovasc Thorac Surg. 2011 Feb. 12(2):243-53. [Medline].

  13. Habib G, Thuny F, Avierinos JF. Prosthetic valve endocarditis: current approach and therapeutic options. Prog Cardiovasc Dis. 2008 Jan-Feb. 50(4):274-81. [Medline].

  14. Nataloni M, Pergolini M, Rescigno G, Mocchegiani R. Prosthetic valve endocarditis. J Cardiovasc Med (Hagerstown). 2010 Dec. 11(12):869-83. [Medline].

  15. Akhtar RP, Abid AR, Zafar H, Khan JS. Aniticoagulation in patients following prosthetic heart valve replacement. Ann Thorac Cardiovasc Surg. 2009 Feb. 15(1):10-7. [Medline].

  16. Daniels PR, McBane RD, Litin SC, Ward SA, Hodge DO, Dowling NF, et al. Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. Thromb Res. 2009 Feb 19. [Medline].

  17. Botta L, Bechan R, Yilmaz A, Di Bartolomeo R. Prosthetic valve endocarditis due to Brucella: successful outcome with a combined strategy. J Cardiovasc Med (Hagerstown). 2009 Mar. 10(3):257-8. [Medline].

  18. Jeejeebhoy FM. Prosthetic heart valves and management during pregnancy. Can Fam Physician. 2009 Feb. 55(2):155-7. [Medline].

  19. Shapira Y, Vaturi M, Sagie A. Hemolysis associated with prosthetic heart valves: a review. Cardiol Rev. 2009 May-Jun. 17(3):121-4. [Medline].

  20. Lengyel M. Diagnosis and treatment of left-sided prosthetic valve thrombosis. Expert Rev Cardiovasc Ther. 2008 Jan. 6(1):85-93. [Medline].

  21. Yaffee DW, Smith DE 3rd, Ursomanno PA, et al. Management of blood transfusion in aortic valve surgery: impact of a blood conservation strategy. Ann Thorac Surg. 2013 Nov 19. [Medline].

  22. Janeczko LL. Blood conservation strategy helpful in aortic valve replacement. Reuters Health Information. December 16, 2013. [Full Text].

  23. Brennan JM, Edwards FH, Zhao Y, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol. 2012 Sep 11. 60(11):971-7. [Medline].

  24. [Guideline] Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007 Oct 9. 116(15):1736-54. [Medline].

  25. Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Catheter Cardiovasc Interv. 2008 Sep 1. 72(3):E1-12. [Medline].

  26. [Guideline] Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A, et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis. The Task Force on Infective Endocarditis of the European Society of Cardiology. France: European Society of Cardiology. 2004. [Full Text].

  27. American College of Obstetricians and Gynecologists. ACOG Committee Opinion: safety of Lovenox in pregnancy. Obstet Gynecol. 2002 Oct. 100(4):845-6. [Medline].

  28. Baddour LM, Wilson WR, Bayer AS. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2005 Jun 14. 111(23):e394-434. [Medline].

  29. Bussey HI. An overview of anticoagulants, antiplatelet agents, and the combination in patients with mechanical heart valves. J Heart Valve Dis. 2004 May. 13(3):319-24. [Medline].

  30. Butany J, Ahluwalia MS, Munroe C, et al. Mechanical heart valve prostheses: identification and evaluation (erratum). Cardiovasc Pathol. 2003 Nov-Dec. 12(6):322-44. [Medline].

  31. Butany J, Fayet C, Ahluwalia MS, et al. Biological replacement heart valves. Identification and evaluation. Cardiovasc Pathol. 2003 May-Jun. 12(3):119-39. [Medline].

  32. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994 Feb. 89(2):635-41. [Medline].

  33. [Guideline] Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. Circulation. 1997 Jul 1. 96(1):358-66. [Medline].

  34. Das M, Twomey D, Al Khaddour A, Dunning J. Is thrombolysis or surgery the best option for acute prosthetic valve thrombosis?. Interact Cardiovasc Thorac Surg. 2007 Dec. 6(6):806-11. [Medline].

  35. Goldman ME. Echocardiographic doppler evaluation of prosthetic valve function and dysfunction. Adv Cardiol. 2004. 41:179-84. [Medline].

  36. Kahn S. Long-term outcomes with mechanical and tissue valves. J Heart Valve Dis. 2002. 11, Suppl 1:S8-S14.

  37. [Guideline] Lengyel M, Fuster V, Keltai M, et al. Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. Consensus Conference on Prosthetic Valve Thrombosis. J Am Coll Cardiol. 1997 Nov 15. 30(6):1521-6. [Medline].

  38. MacKenzie GS, Heinle SK. Echocardiography and Doppler assessment of prosthetic heart valves with transesophageal echocardiography. Crit Care Clin. 1996 Apr. 12(2):383-409. [Medline].

  39. Mehlman DJ. A pictorial and radiographic guide for identification of prosthetic heart valve devices. Prog Cardiovasc Dis. 1988 May-Jun. 30(6):441-64. [Medline].

  40. O'Riordan M. FDA Approves Medtronic's CoreValve for Inoperable Patients. Medscape [serial online]. Available at Accessed: January 26, 2014.

  41. Piper C, Kprfer R, Horstkotte D. Prosthetic valve endocarditis. Heart. 2001 May. 85(5):590-3. [Medline].

  42. Roudaut R, Lafitte S, Roudaut MF, et al. Fibrinolysis of mechanical prosthetic valve thrombosis: a single-center study of 127 cases. J Am Coll Cardiol. 2003 Feb 19. 41(4):653-8. [Medline].

  43. Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001 Jan. 119(1 Suppl):220S-227S. [Medline].

  44. Vongpatanasin W, Hillis LD, Lange RA. Prosthetic heart valves. N Engl J Med. 1996 Aug 8. 335(6):407-16. [Medline].

  45. Willson A, Webb J. Transcatheter treatment approaches for aortic valve disease. Int J Cardiovasc Imaging. 2011 Dec. 27(8):1123-32. [Medline].

Medtronic Hall mitral valve. Reproduced with permission from Medtronic, Inc.
The Hancock M.O. II aortic bioprosthesis (porcine). Reproduced with permission from Medtronic, Inc.
Starr-Edwards Silastic ball valve mitral Model 6120. Reproduced with permission from Baxter International, Inc.
Carpentier-Edwards Duralex mitral bioprosthesis (porcine). Reproduced with permission from Baxter International, Inc.
Carpentier-Edwards Perimount pericardial aortic bioprosthesis. Reproduced with permission from Baxter International, Inc.
St. Jude Medical mechanical heart valve. Photograph courtesy of St. Jude Medical, Inc. All rights reserved. St. Jude Medical is a registered trademark of St. Jude Medical, Inc.
Edwards Sapien transcatheter aortic valve.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.